 Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the body, is providing an update on its Phase 1 trial of CUE-101 monotherapy as second-line or later therapy for patients with HPV recurrent andor metastatic head and neck squamous cell carcinoma HNSCC. As of June 15, 2020, the ongoing Phase 1, first-in-human, multicenter trial has enrolled 13 patients, with a majority of patients having received multiple cycles of therapy. Out of the 13 patients enrolled, there are six patients presently remaining on study for ongoing data generation. 